亚洲欧美精品在线-亚洲欧美精品中文字幕在线观看-亚洲欧美精品综合在线观看-亚洲欧美精选-亚洲欧美久久-亚洲欧美久久精品

Hello! Welcome to the official website of Betta Pharmaceuticals!
Service Hotline:+86-571-86130357     Add to Favorites | Online Feedback 中文


Icotinib hydrochloride is a National Class 1.1 new drug that is independently developed by Betta Pharmaceuticals Co., Ltd. for nearly a decade. It is also China's first small molecule targeted anti-cancer drug. Icotinib is a potent and highly selective oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and it is used for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients carrying EGFR mutations. 
On June 7th, 2011, Icotinib hydrochloride was approved by the National Medical Products Association (NMPA), fulfilling the unmet medical needs in China.
On August 12th, 2011, the market launch of Icotinib hydrochloride was held in the Great Hall of the People in Beijing. It was praised as a groundbreaking scientific and technological achievement in the China healthcare industry.
In 2012, Icotinib hydrochloride was included on Citeline’s “Pharm R&D Annual Review for 2012”, which was the first time a Chinese innovative drug was included on such report.
On August 13th, 2013, the phase III ICOGEN clinical trial results of Icotinib hydrochloride were published on the Lancet Oncology (Shi, Y., et al., The Lancet Oncology 14 (10) p953-961). Professor of the University of Colorado, Dr. David Camidge, commented that Icotinib has opened a new era of anticancer drug research in China, which is a significant milestone in the global oncology research.

1698306007803090.png

In 2012 and 2014, icotinib hydrochloride won the Golden Prize of Chinese Patent Award for its composition of matter and the crystal form patents.
In 2015, icotinib hydrochloride won “First Prize of National Science and Technology Progress Award 2015”.
In 2016, icotinib hydrochloride won “Chinese Industry Award”. In the same year, it was included in the first round of the price negotiation with the Chinese National Health Commission and created a new model for medical insurance negotiation, which reduced the burden of Chinese patients.
In 2017, icotinib hydrochloride was enlisted on the National Reimbursement Drug List (NRDL). On July 19th, the BRAIN clinical study results of icotinib hydrochloride for NSCLC brain metastasis treatment were published in the Lancet Oncology (Jin-Ji, Y., et al., The Lancet Oncology 5 (9) p707-716). It is the first phase III study of EGFR TKI targeting NSCLC patients with brain metastasis, and this treatment is recommended in the clinical guide. On August 23rd, the first-line clinical study of icotinib hydrochloride in NSCLC patients carrying EGFR mutations was published in the Annual of Oncology, which provided clinical support for its use in the first-line setting.
In 2018, icotinib hydrochloride was included on the National Essential Drug List (EDL), giving access to more Chinese patients.
In 2019, icotinib hydrochloride was included on the General Drug Access Catalogue of National Medical Insurance, further reducing the economic burden of NSCLC patients.



1.png

主站蜘蛛池模板: 久久久久无码精品国产av网站 | 久久久久久精品人妻免费影视网 | 欧美日韩另类在线专区卡通 | 在线视频 国产精品 中文字幕 | 美女诱惑性感揉胸 | 国产毛多水多女人A片 | 国产精品99久久久 | 国产a毛片精品视频日日夜 国产a毛片一级视频 | 91精品啪在线观看国产色 | 精品国产乱码久久久久久蜜 | 国产精品无码无片在线观看3d | 久久精品国产一区二区三区四区 | 久久久久99精品成人片直播 | 乱人伦精品视频在线观看 | 精品国产一区二区三区香蕉在线 | 精品成人免费一区二区不卡 | 糖心vlog一区二区三区在线 | 色即是空2字幕 | 久久久国产成人一区二区 | 欧美日韩国产综合草草 | 国产不卡的一区二区三区四区 | 国内精品久久人妻无码网站 | 久久99国产一区二区三区 | 成人网站在线观看 | 国产精品538一区二区在线 | 日韩欧美国产91丝袜 | av无码精品一区二区三区 | 欧美美女一区 | 99久久无码一区人妻a片蜜臀 | 国产真实强奷网站在线播放 | 国产a视频精品免费观看 | 美女扒开胸罩露出奶头的动态图片 | 一区二区三区四区在线免费观看 | 天美麻花星空大象在线看 | 丰满人妻系列无码专区 | 国产精品中文久久久久久 | 国产毛片一级不卡 | 久久久国产精品欧美狂野 | 国产一区二区三不卡高清 | 伊人网在线观看 | 久久精品一卡二卡三卡四卡视频版 |